Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;42(3):339-355.
doi: 10.1016/j.det.2024.02.001. Epub 2024 Mar 13.

Biologics for Psoriasis

Anthony Mitchel Wride  1 , Gloria F Chen  1 , Sarah L Spaulding  1 , Elizabeth Tkachenko  1 , Jeffrey M Cohen  2
Affiliations
Review

Biologics for Psoriasis

Anthony Mitchel Wride et al. Dermatol Clin. 2024 Jul.

Abstract

Biologic therapies targeting tumor necrosis factor alpha (TNF-α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized the treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-α inhibitors.

Keywords: Biologics; Efficacy; Psoriasis; Safety.

PubMed Disclaimer

Conflict of interest statement

Disclosure J.M. Cohen serves on a data and safety monitoring board for Advarra. The remaining authors have no conflicts of interest to declare.

MeSH terms